Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 2/20 | 0.30 |
| ▸ | BCR | P11274 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31574156 | 1.00 | KMT2A (0.33) | KMT2AMEN1KDM4EUSP2TP53 | |
| SCHEMBL30515553 | 0.81 | MAPT (0.34) | KMT2AMEN1KDM4ETP53HSP90AA1 | |
| SCHEMBL1633632 | 0.81 | MAPT (0.34) | KMT2AMEN1KDM4ETP53HSP90AA1 | |
| SCHEMBL30782222 | 0.78 | ABL1 (0.33) | KMT2AMEN1EGFRRPS6KA5ABL1 | |
| SCHEMBL18073578 | 0.78 | KDM4E (0.35) | KMT2AKDM4ETP53HTTSMN1; SMN2 | |
| SCHEMBL38652759 | 0.74 | NQO2 (0.45) | KMT2AMEN1KDM4ESMN1; SMN2EGFR | |
| SCHEMBL559708 | 0.73 | BACE1 (0.46) | KMT2AMEN1KDM4ESMN1; SMN2EGFR | |
| SCHEMBL31114211 | 0.73 | BACE1 (0.46) | KMT2AMEN1KDM4ESMN1; SMN2EGFR | |
| SCHEMBL1635008 | 0.73 | NQO2 (0.41) | KMT2AMEN1KDM4EHSP90AA1EGFR | |
| SCHEMBL13313261 | 0.73 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739306-A2 | POLO-LIKE KINASE 1 INHIBITORS | Cervero Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-119968360-A | Quinazoline compound and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024131938-A1 | QUINAZOLINE COMPOUND AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2024-06-27 | — | — | WO | disclosed |
| WO-2023143135-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514728-A | Quinazoline derivative and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3078660-B1 | NOVEL QUINAZOLINE DERIVATIVE | MYCHUNTER THERAPEUTICS INC (JP) | 2022-07-13 | — | — | EP | disclosed |
| US-9682961-B2 | Quinazoline derivative | CARNA BIOSCIENCES, INC. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9682961-B2 | Quinazoline derivative | CARNA BIOSCIENCES, INC. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| CN-101454294-A | Quinazolines for pdk1 inhibition | NOVARTIS AG (CH) | 2009-06-10 | — | — | CN | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | KMT2A 1044/4885MEN1 1891/4885KDM4E 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.